Sirolimus: Defining nephrotoxicity in the renal transplant recipient

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 2, 2007, Pages 198-199

  Tomlanovich, Stephen J ^a   Vincenti, Flavio ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

CHEMICALLY INDUCED DISORDER; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NOTE; POSTOPERATIVE COMPLICATION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; SIROLIMUS;

EID: 34548859562     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00340107     Document Type: Editorial

References (19)

1. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicenter study. The Rapamune US Study Group. The Lancet 356: 194-202, 2000
2. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou T-C, Kahan B: Pharmacokinetic interactions augment toxicities of sirolimus/ cyclosporine combinations. J Am Soc Nephrol 12: 1059-1071, 2001
3. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmax S, Hayry P, Neylan JF; for the Rapamune Maintenance Regimen Trial: Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4:953-961, 2004
4. McTaggart RA, Gottlieb D, Brooks J, Bacchetti P, Roberts JP, Tomlanovich S, Feng S: Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3: 416-423, 2003
5. Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R: A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 14: 550-554, 2000
6. Smity KD, Wrenshall LE, Nicosia RF, Pichler R, Marsh CL, Alpers CE, Pohssar N, Davis CL: Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 14: 1037-1045, 2003
7. Coombes JD, Mreich E, Liddle C, Rangan GK: Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 68: 2599-2607, 2005
8. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo, L, Schena FP, Grandaliano G: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317-1323, 2005
9. Letavernier E, Pe'raldi M-N, Pariente A, Morelon E, Legendre C: Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 80: 1198-1203, 2005
10. Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, de las Cuevas X, Oppenheimer F: Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 21: 488-493, 2006
11. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F: Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 21: 3252-3257, 2006
12. van den Akkher JM, Wetzels JFM, Hoitsma AJ: Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 70: 1355-1357, 2006
13. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostang L: Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inbibitors to sirolimus. Nephrol Dial Transplant 20: 2517-2523, 2005
14. Skhiri H, Morelon E, Noel L-H, Mamzer-Bruneel M-F, Legendre C, Peraldi M-N, Kreis H: Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus. Transplant Int 8: 458-460, 2005
15. Straathof-Galema L, Wetzels JFM, Dijkman DBPM, Steenbergen EJ, Hilbrands LB: Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 6: 429-433, 2006
16. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AMJ: Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 5: 2318-2323, 2005
17. Bonegio RGB, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubuloin-terstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063-2072, 2005
18. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, Wochos DN, Synhavsky A, Hippler S, Larson TS, Bagniewski SM, Velosa JA; for the Mayo Nephrology Collaborative Group. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 10: 1288-1292, 2004
19. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen J-P, Pe'raldi M-N, HeIal I, Noel L-H, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326-333, 2007